Biotech rally rests on fundamentals, M&A appetite, says ROTY's Faison
Seeking Alpha ·
The recent rally in biotechnology stocks is being driven by improving fundamentals and a resurgence in merger activity rather than speculative excess, according to Jonathan Faison, founder of ROTY Biotech Community.
DYAX Investor Sentiment
Bullish (Long) 41% · Bearish (Short) 59%
465 participants
Related News
- Earnings Snapshot: Delta Air Lines tops June quarter guidance; forecasts Q3 earnings growth of $2.00 to $2.50/shr
- Electric Vehicles Today - Driving Toward a Trillion-Dollar Future
- Medaro Mining names new CEO
- Delta Air Lines Non-GAAP EPS of $1.56 beats by $0.06, revenue of $19.8B beats by $950M
- ChipMOS posts record monthly, quarterly revenue since 2014
- Ionis Pharmaceuticals reiterates FY26 outlook, unchanged from April projections